Merck Serono Company Description
Fertile minds at Merck Serono S.A. (formerly Serono S.A.) help people around the world combat infertility. One of the world's top biotechs, Merck Serono focuses on recombinant genetic engineering to develop drugs. It is a leader in reproductive health, with flagship drug Gonal-F at the head of its infertility product line. However, over half of the company's sales come from its beta interferon drug (Rebif), used to treat multiple sclerosis. The firm also focuses on neurological, dermatological, metabolic, and growth disorders. Merck KGaA acquired the company in 2007 for $13 billion.
View the Comprehensive Company Description for Merck Serono
The Company Description provides a historical perspective of Merck Serono's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Merck Serono's evolution in the marketplace.
